Latest data reveals BioLegend’s growth into the top five antibody suppliers
5
Min Read
In this blog:
- How has BioLegend’s antibody market share changed over the past decade?
- Where are they seeing strong performance?
- Download the latest data on the top five antibody suppliers
CiteAb began by collecting information on antibody use in scientific publications. Our data now powers a world-leading search tool to help scientists find reagents, and can be licensed for competitive analysis and product management insights.
The research antibody market is one of the most competitive spaces in the life sciences, spanning over 8 million antibodies and more than 400 suppliers.
Recent analysis using CiteAb data has revealed a notable shift – BioLegend have entered the top five rankings of antibody company market share.
In this article, we dig into their trajectory, where growth has been the strongest, and how this compares to broader market trends.
The research antibody market at a glance
With our AI-driven data collection technology, we are able to build a picture of global research activity by understanding reagent use in life science publications. Citation share serves as both a proxy for historical product sales and a leading indicator of future purchasing trends.
For many years, the antibody market has been led by:
- Abcam (NYSE: DHR)
- Cell Signaling Technology
- Thermo Fisher Scientific (Invitrogen) (NYSE: TMO)
- MilliporeSigma (ETR: MRK)
- Santa Cruz Biotechnology
Impressively, in a previous analysis into antibody market supplier share, we noted that these suppliers accounted for approximately 65% of the total antibody market. This demonstrates strong support for scientists working in the antibody space.
Updated analysis now shows that, BioLegend, part of Revvity (NYSE:RVTY), holds the fourth-largest overall antibody market share. Our data shows they took this position in 2023 and have maintained it since.
Spotlight on BioLegend’s trajectory in the antibody market
We have commented on BioLegend’s growth over the years, noting a steadily increasing antibody market share.
Looking at primary and secondary antibody citations across all countries shows many consecutive years of upward movement.
BioLegend ranked in 6th position in the research antibody market between 2019 and 2022, before shooting up to fourth in 2023.
What factors may have contributed to BioLegend’s rising share?
Antibody focus and product mix
Historically, BioLegend have focussed on monoclonal antibodies and flow cytometry reagents.
In 2024, we found that monoclonal antibodies accounted for 65% of antibody citations in the overall market, with a growing share.
This suits BioLegend’s specialism, given 98% of their citations are from monoclonals. In fact, they have over 27,000 monoclonals available, meaning they are well positioned to meet the market’s needs.
Acquisitions and partnerships
BioLegend were acquired by Revvity (formerly PerkinElmer) at the end of 2021. This acquisition aimed to scale their leading position in the life sciences. [1]
Indeed, we can see that following a short plateau in 2021, BioLegend’s share has continued to grow, against the backdrop of an uncertain and highly competitive market landscape.
You can read more analysis into this acquisition in our Life Science M&A blog here.
In the years since, the company have been active creating new solutions for the antibody market. An example of which includes a partnership using their TotalSeq antibodies within the Scale Biosciences platform, to support immunology and oncology research, in 2024. [2]
Strength in influential geographical hotspots
Drilling down into our antibody market data further, we took a look at the top five antibody markets in 2024. BioLegend had a strong position in each.
As we may expect, they were particularly strong in their home country, the US (their offices are based in San Diego). Their position has also been rising over the years in the US.
China is a particularly significant and fast growing research market. In a previous analysis, we revealed that China has overtaken the US by antibody citation share, demonstrating its influence. (You can read more about the influence of China in the antibody space in our ten years of reagent data analysis here.)
Significantly, we noticed that BioLegend were gaining ground in China.
All these factors and more have culminated in BioLegend’s entry into the top five.
What this means for the antibody market
BioLegend’s entry into the top five signals increased competition amongst leading suppliers and a continued opportunity for vendors to challenge established players.
In fact, in a previous antibody market analysis we commented on the strong performance of GeneTex and Abclonal, alongside BioLegend, which you can read about in our research antibody companies to watch blog here.
We’ve also noticed companies like Proteintech growing in this space, demonstrated in the top 100 cited antibody data, released in 2025.
We’ll be watching these growing companies, and others, in the antibody space to see how the market continues to evolve.
You can sign up for our newsletter below to be the first to hear when we release new analysis into reagent markets.
The data behind this antibody market analysis
For this analysis, we dived into our database of ten years worth of data spanning over 8 million antibody products.
We collect information on applications, research areas, validations and much more for primary, secondary, polyclonal, monoclonal and recombinant antibodies to give as much colour as possible to how products were used in the literature.
Our market data supports internal analysis for targeted marketing and sales, competitor benchmarking, and product strategy development. Learn more about our data solutions here.
Download data on the top five antibody suppliers below
Remember, you can download data on the top five antibody suppliers to see what’s changed since 2022 below.
Sign up for data
Something seems to have gone wrong while loading the form.
Drop us a message and we can send you the data directly.
References
